Drug Profile

Compound 451238

Alternative Names: Compound 451238

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Apr 2020 Compound 451238 is still in phase I/II trials for Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in United Kingdom (unspecified route) (NCT03602833)
05 Nov 2018 Phase-I/II clinical trials in Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in United Kingdom (unspecified route) (NCT03602833)
29 Jul 2018 Royal Marsden NHS Foundation Trust and Merck KGaA plan a phase I/II trial for Soft-tissue sarcoma (Combination therapy) in United Kingdom (NCT03602833) (EudraCT2017-001316-11)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com